Business Information
The company's principal activities are to develop drug candidates from natural product compounds known as polyketides. Polyketides are naturally made in very small amounts in certain microorganisms and are difficult to make or modify chemically. The company develops polyketides for infectious diseases like gastrointestinal motility disorders, mucus hypersecretion, cancer, immunosuppression and nerve regeneration. The group has collaborative arrangements with hoffman-la roche, inc. And f. Hoffman-la roche ltd., johnson & johnson pharmaceutical research and development, llc, a subsidiary of ortho-mcneil pharmaceutical, inc. And several other research groups, including sloan-kettering institute for cancer research and the national cancer institute.
|
|
Name |
Title
|
Email
|
| Peter Davis | Chmn. | N/A | | Gary Titus | Sr. VP, CFO | N/A | | Albert Kraus | VP - Regulatory Affairs | N/A | | Gary Ashley | VP - Exploratory Research, Kosan Fellow | N/A | | Jane Green | VP - Corporate Communications | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 13,506 | (29,469) | | 2005 | 13,410 | (29,637) | | 2004 | 22,892 | (22,126)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
